Consolidated Statement of Shareholders' Equity - 9 months ended Sep. 30, 2017 - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid-in Capital	Unearned ESOP Shares	Accumulated Other Comprehensive Income (Loss)	Retained Earnings
Beginning balance at Dec. 31, 2016	$ (214,376)	$ (41,110)	$ (1,136)	$ (111,166)	$ 1,233	$ 1,010	$ (63,207)
Beginning balance (in shares) at Dec. 31, 2016		123,098	11,362,716
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(1,257)						(1,257)
Dividends on Series B and Series C preferred stock	(2,432)						(2,432)
Dividends on common stock, $0.19 per share	(2,645)						(2,645)
Issuance of common stock, net of offering expenses of $683	57,151		$ 510	56,641
Issuance of common stock, net of offering expenses of $622 (in shares)			5,100,034
Restricted stock grant			$ 6	(6)
Restricted stock grant (in shares)			58,090
Conversion of Series C preferred stock to common stock		$ (123)	$ 1	122
Conversion of Series C preferred stock to common stock (in shares)		(1,223)	(6,791)
ESOP shares released for allocation	316			50	266
Exercise of stock options	266		$ 2	264
Exercise of stock options (in shares)			20,498
Vested restricted stock (in shares)			700
Stock option and restricted stock compensation expense	85			85
Change in accumulated other comprehensive income (loss)	1,783					1,783
Ending balance at Sep. 30, 2017	$ (267,643)	$ 40,987	$ (1,655)	$ (168,322)	$ 967	$ (773)	$ (56,873)
Ending balance (in shares) at Sep. 30, 2017		121,875	16,548,829